Terlok 150 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

terlok 150 mg filmom obložene tablete

edicta pharm d.o.o., klaićeva 62, zagreb - erlotinibum - filmom obložena tableta - 150 mg - urbroj: jedna filmom obložena tableta sadrži 150 mg erlotiniba (u obliku erlotinibklorida)

Terlok 25 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

terlok 25 mg filmom obložene tablete

edicta pharm d.o.o., klaićeva 62, zagreb - erlotinibum - filmom obložena tableta - 25 mg - urbroj: jedna filmom obložena tableta sadrži 25 mg erlotiniba (u obliku erlotinibklorida)

Varlota 150 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

varlota 150 mg filmom obložene tablete

zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - erlotinibklorid - filmom obložena tableta - 150 mg - urbroj: jedna filmom obložena tableta sadrži 150 mg erlotiniba (u obliku erlotinibklorida)

Verzenios Europska Unija - hrvatski - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - neoplazme dojki - antineoplastična sredstva - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.